be prepaid in whole or in part without penalty at any time. The principal amount of the loan is payable in three equal annual installments on the fourth, fifth and sixth anniversaries of the facility agreement, except that, if Discovery Labs achieves certain revenue or market capitalization targets, the principal payments due on the fourth and fifth anniversaries could be deferred for one year. Accordingly, if the milestones are achieved, payment of the principal amount could be deferred until the maturity date of the loan in 2019. The outstanding principal amount of the loan at any time will accrue interest at a rate of 8.75% per annum, payable quarterly in cash. The facility agreement contains customary terms and conditions but does not require Discovery Labs to meet minimum financial and revenue performance covenants. In connection with each advance,
Deerfield will receive a transaction fee equal to 1.5% of the amount disbursed. In connection with the initial advance,
Deerfield will receive warrants to purchase 2.3 million shares of common stock, par value $.001 per share (Common Stock), at an exercise price of $2.81 per share, which represents a premium of 24% over the closing price of the Company's common stock preceding the execution of the facility agreement. Upon disbursement of the $20 million advance,
Deerfield will receive warrants to purchase an additional 4.7 million shares of Common Stock at the same exercise price per share of Common Stock. All of the warrants will expire on the sixth anniversary date of the facility agreement.
Additional information about the facility and the terms of the related agreements is included in a Current Report on Form 8-K that is expected to be filed today with the Securities and Exchange Commission.
This press release is neither an offer to sell nor a solicitation of an offer to bu
'/>"/>
SOURCE Discovery Laboratories, Inc. Copyright©2012 PR Newswire. All rights reserved | |
Page: 1 2 3 4 5 Related biology technology :1.
Chicago to Welcome Data Science, Big Data and Data Mining Leaders at the 19th International ACM Knowledge Discovery and Data Mining Conference, KDD 20132.
Glenmark Announces a New Discovery and the Initiation of IND Enabling Studies of a Novel Monoclonal Antibody Targeting OX403.
Discovery in synthetic biology takes us a step closer to new industrial revolution4.
Automated design for drug discovery5.
Japan Bioinformatics Announces Study on Leading Mapping Tools for DNA Mutation Discovery6.
Research discovery could revolutionize semiconductor manufacture7.
Stem Cell Pioneer Recognized for 20 Years of Discovery and Innovation8.
Discovery could hold the key to super-sensory hearing9.
Sweet diesel! Discovery resurrects process to convert sugar directly to diesel10.
New discovery shows promise in future speed of synthesizing high-demand nanomaterials11.
UCF nanoparticle discovery opens door for pharmaceuticals